News

Pfizer's combination therapy improves survival in bladder cancer trial

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer raises 2025 profit forecast as cost-cutting program gains traction

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
mlive on MSN1d

‘Potential exposure’ at Portage Pfizer plant sends people to hospital, MIOSHA investigating

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?

Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...
STAT3d

Pfizer drug extends survival for some bladder cancer patients

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

Starboard takes new position in TripAdvisor, adds Salesforce and Pfizer among Q2 moves

Hedge fund Starboard in Q2 took a new position in TripAdvisor (NASDAQ:TRIP) and iShares Russell 2000 ETF (IWM), boosted its ...